VOR240816C2500
- 0.05
- 0.000.00%
Vor Biopharma Newsroom
Buy Rating Affirmed for Vor Biopharma Amid Promising Clinical Trials and Market Potential Expansion
Buy Rating Affirmed: Vor Biopharma's Clinical and Financial Fortitude
Vor Biopharma Analyst Ratings
Silvan Tuerkcan Reaffirms Buy Rating for Vor Biopharma Citing Clinical Progress and Expanding Market Potential
Vor Biopharma Analyst Ratings
Vor Biopharma (VOR) Receives a Buy From Wedbush
Promising Clinical Trials and Stable Financial Outlook Bolster Buy Rating for Vor Biopharma
Barclays Reaffirms Their Buy Rating on Vor Biopharma (VOR)
Vor Biopharma Analyst Ratings
Buy Rating Affirmed for Vor Biopharma on Clinical Progress and Market Potential
Analysts Offer Insights on Healthcare Companies: Vor Biopharma (VOR), Inotiv (NOTV) and Vericel (VCEL)
Stifel Nicolaus Sticks to Its Buy Rating for Vor Biopharma (VOR)
Analysts Are Bullish on Top Healthcare Stocks: Immatics (IMTX), Vor Biopharma (VOR)
Vor Biopharma Analyst Ratings
Analysts Offer Insights on Healthcare Companies: TELA Bio (TELA) and Vor Biopharma (VOR)
Stifel Cuts Price Target on Vor Biopharma to $12 From $15, Maintains Buy Rating
Analysts' Opinions Are Mixed on These Healthcare Stocks: Vor Biopharma (VOR), Roche Holding AG (OtherRHHVF) and Trevi Therapeutics (TRVI)
Vor Biopharma Analyst Ratings
Analysts Offer Insights on Healthcare Companies: Exelixis (EXEL), IDEAYA Biosciences (IDYA) and Vor Biopharma (VOR)
Analysts Have Conflicting Sentiments on These Healthcare Companies: LivaNova (LIVN), Vor Biopharma (VOR) and Neurogene (NGNE)